Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Birinapant

Generic Name: Birinapant

Drug Type: Small Molecule

Chemical Formula: C_₄₂H_₅₆F_₂N_₈O_₆

CAS Number: 1260251-31-7

Unique Ingredient Identifier: 6O4Z07B57R

Overview

Birinapant has been investigated for the treatment of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Background

Birinapant has been investigated for the treatment of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

Phase 2

Terminated

Posted: 2014/05/28

Sponsor:

TetraLogic Pharmaceu...

ID:NCT02147873

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

Phase 1

Completed

Posted: 2013/09/12

Sponsor:

TetraLogic Pharmaceu...

ID:NCT01940172

Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

Phase 1

Completed

Posted: 2013/04/10

Sponsor:

TetraLogic Pharmaceu...

ID:NCT01828346

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Phase 2

Terminated

Posted: 2012/09/07

Sponsor:National Cancer Inst...

ID:NCT01681368

A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia

Phase 1

Terminated

Posted: 2011/12/07

Sponsor:Abramson Cancer Cent...

ID:NCT01486784

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy